| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 11, 2013
LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
-
Feb 25, 2013
LEXINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
-
Feb 20, 2013Conference Call to Discuss Results and Provide 2013 Outlook Today at 9:00 a.m. EST
LEXINGTON, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
-
Feb 19, 2013Brings Over 20 Years of Experience in Cancer Research, Drug Discovery and Development, Including Nexavar® (sorafenib) and PD-0332991 (palbociclib)
LEXINGTON, Mass., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
-
Feb 15, 2013
LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...